The FDA rounded out the month with the approval of remibrutinib (Rhapside; Novartis), a highly selective Bruton tyrosine kinase inhibitor (BTKi), for patients with chronic spontaneous urticaria (CSU) ...
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced three abstracts from its clinical development programs will be presented at the upcoming ...
Abstract: Acromegaly, a chronic endocrine disorder, requires early diagnosis to prevent severe complications. Existing deep-learning-based diagnostic methods often prioritize accuracy at the expense ...
Understanding the chemotherapy drugs you’re getting can help you feel more informed and prepared. Knowing the group that the chemo belongs to—and its exact name—can give you helpful context for why ...
hUNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Sexual, Reproductive, Maternal, Child, Adolescent Health and ...
PITTSBURGH, Oct. 13, 2025 /PRNewswire/ — PANTHERx ® Rare has been chosen by Chiesi as the exclusive specialty pharmacy to ...
More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...
The FDA has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis, a rare, progressive lung disease that can cause scarring and breathing difficulties. The approval marks the ...
It’s not uncommon for breast cancer patients in the rural South to travel hundreds of miles to reach the medical practice run by Dr. Phillip Ley, a cancer surgeon in Jackson, Mississippi. For those ...
Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. Sean “Diddy” Combs was sentenced Friday to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback